Application of recombinant human interleukin-11 (rhIL-11) for acute myeloid leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 86-87, 2009.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-472171
Biblioteca responsável:
WPRO
ABSTRACT
Objective To observe the therapeutic effect and adverse effect for chemthrombocytopenic of rhIL-11 in chemotherapy for acute myeloid leukemia. Methods We adopted a randomized, blank-control, crossover trial of rhIL-11 in 16 newly diagnosed patients with acute myeloid leukemia. The treatment group were accepted chemotherapy by DA or TA. rhIL-11 (25μg·kg-1·d-1, subcutaneously) was administered from 24 h after chemotherapy and continued for seven to fourteen days. The changes of platelet counts were observed. Results The group by chemotherapy had higher platelet counts than control after rhIL-11 treatment and platelet transfusion frequency was reduced. The adverse effect of rhIL-11 was light, including fatigue, muscular soreness and low-grade fever. Conclusion rhIL-11 is safe and effective in reducing chemotherapy thrombocytopenia.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Ensaio clínico controlado
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2009
Tipo de documento:
Artigo